ProKidney Corp. (NASDAQ:PROK) Insider Buys $195,716.65 in Stock

ProKidney Corp. (NASDAQ:PROK) insider Control Empresarial De Capital acquired 268,105 shares of the business’s stock in a transaction dated Monday, April 14th. The stock was bought at an average cost of $0.73 per share, with a total value of $195,716.65. Following the acquisition, the insider now owns 72,862,330 shares in the company, valued at $53,189,500.90. The trade was a 0.37 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Control Empresarial De Capital also recently made the following trade(s):

• On Thursday, April 10th, Control Empresarial De Capital purchased 1,032,218 shares of ProKidney stock. The stock was purchased at an average price of $0.61 per share, with a total value of $629,652.98.

ProKidney Price Performance

ProKidney stock opened at $0.80 on Thursday. ProKidney Corp. has a fifty-two week low of $0.46 and a fifty-two week high of $4.44. The firm has a market capitalization of $234.16 million, a PE ratio of -1.45 and a beta of 1.52. The company’s 50-day moving average is $1.07 and its 200-day moving average is $1.52.

ProKidney (NASDAQ:PROK) last released its quarterly earnings data on Monday, March 17th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.03). The business had revenue of $0.08 million during the quarter. As a group, analysts expect that ProKidney Corp. will post -0.57 EPS for the current year.

Hedge Funds Weigh In On ProKidney

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd bought a new position in shares of ProKidney in the third quarter valued at about $41,000. ProShare Advisors LLC raised its holdings in ProKidney by 57.3% in the 4th quarter. ProShare Advisors LLC now owns 30,879 shares of the company’s stock valued at $52,000 after acquiring an additional 11,250 shares during the period. Sei Investments Co. acquired a new stake in ProKidney during the fourth quarter worth approximately $69,000. The Manufacturers Life Insurance Company boosted its holdings in shares of ProKidney by 54.6% during the third quarter. The Manufacturers Life Insurance Company now owns 37,981 shares of the company’s stock worth $73,000 after acquiring an additional 13,415 shares during the period. Finally, Susquehanna Fundamental Investments LLC acquired a new position in shares of ProKidney in the fourth quarter valued at approximately $88,000. 51.59% of the stock is owned by institutional investors.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.